KZR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Kezar Life Sciences Inc

NASDAQ | KZR

6.15

USD

$0.00

(

0.00%

)

At Close (As of Dec 2, 2025)

$45.55M

Market Cap

-

P/E Ratio

-8.44

EPS

$7.27

52 Week High

$3.53

52 Week Low

HEALTHCARE

Sector

KZR Chart

Recent Chart
Price Action

KZR Technicals

Tags:

KZR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1M
Total Revenue $0
Cost Of Revenue $1M
Costof Goods And Services Sold $1M
Operating Income -$91M
Selling General And Administrative $23M
Research And Development $66M
Operating Expenses $91M
Investment Income Net -
Net Interest Income $6.9M
Interest Income $8.5M
Interest Expense $1.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$84M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$84M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$81M
Net Income -$84M

Revenue & Profitability

Earnings Performance

KZR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $145M
Total Current Assets $137M
Cash And Cash Equivalents At Carrying Value $42M
Cash And Short Term Investments $42M
Inventory -
Current Net Receivables $424K
Total Non Current Assets $7.2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $90M
Other Current Assets $4.8M
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $20M
Current Accounts Payable $3.7M
Deferred Revenue -
Current Debt -
Short Term Debt $8.7M
Total Non Current Liabilities $7.4M
Capital Lease Obligations $5.9M
Long Term Debt $5.1M
Current Long Term Debt $5.2M
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $7.9M
Other Non Current Liabilities -
Total Shareholder Equity $117M
Treasury Stock -
Retained Earnings -$434M
Common Stock $7K
Common Stock Shares Outstanding $73M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$74M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1M
Capital Expenditures $29K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $80M
Cashflow From Financing $103K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$84M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1M
Total Revenue $0
Cost Of Revenue $1M
Costof Goods And Services Sold $1M
Operating Income -$91M
Selling General And Administrative $23M
Research And Development $66M
Operating Expenses $91M
Investment Income Net -
Net Interest Income $6.9M
Interest Income $8.5M
Interest Expense $1.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$84M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$84M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$81M
Net Income -$84M

KZR News

KZR Profile

Kezar Life Sciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kezar Life Sciences, Inc. is an innovative clinical-stage biotechnology firm based in South San Francisco, California, specializing in the advancement of small molecule therapies aimed at immune-mediated diseases and cancer. By harnessing its proprietary drug discovery platform, the company is dedicated to meeting urgent medical needs, with a robust and varied pipeline of candidates currently undergoing clinical evaluation. Kezar's strategic emphasis on addressing complex therapeutic challenges positions it as a frontrunner in the biopharmaceutical landscape, with the potential to significantly enhance patient outcomes and transform treatment paradigms in pivotal disease areas.

LPTX
+368.57%
$2.05
PAVS
-29.35%
$0.05
BYND
-3.73%
$1.29
NVDA
+0.85%
$181.46
INTC
+8.64%
$43.47
PLRZ
+131.96%
$7.33
VHAI
0.00%
$0.00
FTEL
-0.83%
$1.19
PLUG
+9.89%
$2.11
CMND
-9.93%
$0.12
TWOH
0.00%
$0.00
BITF
-5.48%
$3.10
ONDS
+6.46%
$8.07
IPG
-1.95%
$24.57
IREN
-15.19%
$41.12
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.00%
$14.24
ASST
-1.42%
$1.03
BMNR
+10.26%
$31.91
SOFI
+1.65%
$29.51
BBD
+1.38%
$3.67
F
-1.51%
$12.96
AAPL
+1.09%
$286.19
ADAP
-15.14%
$0.05
BTBT
-5.46%
$2.25
WBD
+2.76%
$24.53
BAC
-0.09%
$53.19
MARA
+3.38%
$11.91
AMZN
+0.23%
$234.42
ACHR
+2.54%
$7.65
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
NIO
-2.89%
$5.03
SOND
-23.45%
$0.12
YGMZ
-21.06%
$0.08
AMD
-2.05%
$215.24
CAN
+2.04%
$0.96
BMNU
+19.54%
$7.34
RMBL
+60.50%
$3.21
CLSK
-2.62%
$13.71
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ITUB
+2.64%
$7.89
CIFR
-10.41%
$17.64
PLTR
+1.91%
$170.69
SRM
+53.27%
$10.30
IVP
-0.62%
$0.12
GOOGL
+0.29%
$315.81
RIVN
+0.40%
$17.23
BTG
-3.26%
$4.43
GRAB
-0.18%
$5.26
APLD
-0.56%
$28.05
EXK
-1.70%
$9.24
WULF
-7.05%
$14.22
BQ
+41.53%
$2.76
INHD
-15.40%
$0.14
MSTR
+5.78%
$181.33
PLTD
-1.83%
$6.96
KVUE
-2.09%
$16.86
SGMO
+3.47%
$0.44
VALE
+1.57%
$12.89
MRVL
+1.96%
$92.89
WLGS
-5.57%
$0.04
RGTI
+1.83%
$23.88
MTSR
-0.35%
$70.50
SNAP
-0.26%
$7.62
BURU
-0.76%
$0.21
HBAN
+0.12%
$16.56
RIG
-0.91%
$4.31
PCG
-3.28%
$15.32
CRWV
-1.33%
$76.03
HOOD
+2.19%
$125.95
NFLX
+0.20%
$109.35
VICI
-0.52%
$28.44
AFMD
-34.94%
$0.18
GPUS
+6.45%
$0.28
IXHL
+12.12%
$0.39
GOOG
+0.28%
$316.02
VZ
-0.31%
$40.61
BA
+10.14%
$205.38
TMC
+17.74%
$7.40
CHR
-0.91%
$0.04
AG
+2.48%
$15.90
RIOT
-1.67%
$15.22
AVGO
-1.16%
$381.57
SOUN
-2.60%
$11.22
HL
+2.45%
$17.52
VCIG
+0.95%
$1.06
XYZ
-6.58%
$60.11
BTE
0.00%
$3.22
DRCT
-15.28%
$0.10
T
-1.06%
$25.51
NOK
+1.14%
$6.19
TAOP
+32.71%
$2.84
KO
-1.77%
$70.67
ORCL
+0.07%
$201.10
CGC
-1.76%
$1.11
GRYP
-10.38%
$1.38
SMCI
-1.46%
$32.92
LPTX
+368.57%
$2.05
PAVS
-29.35%
$0.05
BYND
-3.73%
$1.29
NVDA
+0.85%
$181.46
INTC
+8.64%
$43.47
PLRZ
+131.96%
$7.33
VHAI
0.00%
$0.00
FTEL
-0.83%
$1.19
PLUG
+9.89%
$2.11
CMND
-9.93%
$0.12
TWOH
0.00%
$0.00
BITF
-5.48%
$3.10
ONDS
+6.46%
$8.07
IPG
-1.95%
$24.57
IREN
-15.19%
$41.12
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.00%
$14.24
ASST
-1.42%
$1.03
BMNR
+10.26%
$31.91
SOFI
+1.65%
$29.51
BBD
+1.38%
$3.67
F
-1.51%
$12.96
AAPL
+1.09%
$286.19
ADAP
-15.14%
$0.05
BTBT
-5.46%
$2.25
WBD
+2.76%
$24.53
BAC
-0.09%
$53.19
MARA
+3.38%
$11.91
AMZN
+0.23%
$234.42
ACHR
+2.54%
$7.65
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
NIO
-2.89%
$5.03
SOND
-23.45%
$0.12
YGMZ
-21.06%
$0.08
AMD
-2.05%
$215.24
CAN
+2.04%
$0.96
BMNU
+19.54%
$7.34
RMBL
+60.50%
$3.21
CLSK
-2.62%
$13.71
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ITUB
+2.64%
$7.89
CIFR
-10.41%
$17.64
PLTR
+1.91%
$170.69
SRM
+53.27%
$10.30
IVP
-0.62%
$0.12
GOOGL
+0.29%
$315.81
RIVN
+0.40%
$17.23
BTG
-3.26%
$4.43
GRAB
-0.18%
$5.26
APLD
-0.56%
$28.05
EXK
-1.70%
$9.24
WULF
-7.05%
$14.22
BQ
+41.53%
$2.76
INHD
-15.40%
$0.14
MSTR
+5.78%
$181.33
PLTD
-1.83%
$6.96
KVUE
-2.09%
$16.86
SGMO
+3.47%
$0.44
VALE
+1.57%
$12.89
MRVL
+1.96%
$92.89
WLGS
-5.57%
$0.04
RGTI
+1.83%
$23.88
MTSR
-0.35%
$70.50
SNAP
-0.26%
$7.62
BURU
-0.76%
$0.21
HBAN
+0.12%
$16.56
RIG
-0.91%
$4.31
PCG
-3.28%
$15.32
CRWV
-1.33%
$76.03
HOOD
+2.19%
$125.95
NFLX
+0.20%
$109.35
VICI
-0.52%
$28.44
AFMD
-34.94%
$0.18
GPUS
+6.45%
$0.28
IXHL
+12.12%
$0.39
GOOG
+0.28%
$316.02
VZ
-0.31%
$40.61
BA
+10.14%
$205.38
TMC
+17.74%
$7.40
CHR
-0.91%
$0.04
AG
+2.48%
$15.90
RIOT
-1.67%
$15.22
AVGO
-1.16%
$381.57
SOUN
-2.60%
$11.22
HL
+2.45%
$17.52
VCIG
+0.95%
$1.06
XYZ
-6.58%
$60.11
BTE
0.00%
$3.22
DRCT
-15.28%
$0.10
T
-1.06%
$25.51
NOK
+1.14%
$6.19
TAOP
+32.71%
$2.84
KO
-1.77%
$70.67
ORCL
+0.07%
$201.10
CGC
-1.76%
$1.11
GRYP
-10.38%
$1.38
SMCI
-1.46%
$32.92
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.